**Name of Journal:** *Artificial Intelligence in Gastrointestinal Endoscopy*

**Manuscript NO:** 67312

**Manuscript Type:** MINIREVIEWS

**Deep learning applied to the imaging diagnosis of hepatocellular carcinoma**

Ballotin VR *et al*. DL and HCC

Vinícius Remus Ballotin, Lucas Goldmann Bigarella, John Soldera, Jonathan Soldera

**Vinícius Remus Ballotin, Lucas Goldmann Bigarella,** School of Medicine, Universidade de Caxias do Sul, Caxias do Sul 95070-560, RS, Brazil

**John Soldera,** Computer Science,Federal Institute of Education, Science and Technology Farroupilha, Santo Ângelo 98806-700, RS, Brazil

**Jonathan Soldera,** Clinical Gastroenterology, Universidade de Caxias do Sul, Caxias do Sul 95070-560, RS, Brazil

**Author contributions:** All authors contributed to study concept and design, to drafting of the manuscript and to critical revision of the manuscript for important intellectual content.

**Corresponding author: Jonathan Soldera, MD, MSc, Associate Professor, Staff Physician,** Clinical Gastroenterology, Universidade de Caxias do Sul, Rua Francisco Getúlio Vargas 1130, Caxias do Sul 95070-560, RS, Brazil. jonathansoldera@gmail.com

**Received:** April 21, 2021

**Revised:** June 5, 2021

**Accepted:** July 19, 2021

**Published online:** August 28, 2021

**Abstract**

Each year, hepatocellular carcinoma is diagnosed in more than half a million people worldwide. It is the fifth most common cancer in men and the seventh most common cancer in women. Its diagnosis is currently made using imaging techniques, such as computed tomography and magnetic resonance imaging. For most cirrhotic patients, these methods are enough for diagnosis, foregoing the necessity of a liver biopsy. In order to improve outcomes and bypass obstacles, many companies and clinical centers have been trying to develop deep learning systems that could be able to diagnose and classify liver nodules in the cirrhotic liver, in which the neural networks are one of the most efficient approaches to accurately diagnose liver nodules. Despite the advances in deep learning systems for the diagnosis of imaging techniques, there are many issues that need better development in order to make such technologies more useful in daily practice.

**Key Words:** Hepatocellular carcinoma; Cirrhosis; Machine learning; Artificial intelligence

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Ballotin VR, Bigarella LG, Soldera J, Soldera J. Deep learning applied to the imaging diagnosis of hepatocellular carcinoma. *Artif Intell Gastrointest Endosc* 2021; 2(4): 127-135

**URL:** https://www.wjgnet.com/2689-7164/full/v2/i4/127.htm

**DOI:** https://dx.doi.org/10.37126/aige.v2.i4.127

**Core Tip:** Hepatocellular carcinoma is diagnosed using imaging techniques, such as computed tomography and magnetic resonance imaging. In order to improve outcomes and bypass obstacles, many companies and clinical centers have been trying to develop deep learning systems that could be able to diagnose and classify liver nodules in the cirrhotic liver. Neural networks have become one of the most efficient approaches to accurately diagnose liver nodules using deep learning systems. Therefore, with the improvement of these techniques in the long term, they could be applicable in daily practice, modifying outcomes.

**INTRODUCTION**

Each year, hepatocellular carcinoma (HCC) is diagnosed in more than half a million people worldwide, and it is the fifth most common cancer in men and the seventh most common cancer in women[1]. The greatest burden of this disease is in developing countries, such as Southeast Asia and Sub-Saharan Africa, where hepatitis B is endemic[2,3].

The incidence of HCC has been rising, unlike many other types of neoplasms[4]. This is expected to change, as the worldwide incidence of viral hepatitis B and C is expected to subdue in the next generation *via* vaccination and treatment, respectively. Nevertheless, the acute rise in the prevalence of nonalcoholic steatohepatitis in the last couple of decades might become a key risk factor for HCC and could become solely responsible for sustaining its incidence, both in the Western and Eastern population[5,6].

Therefore, understanding the diagnostic and therapeutic approaches to this disease is essential, especially if we keep in mind the quintessential basics of prevention and early detection to improve results[7,8].

**DIAGNOSIS OF HCC**

HCC diagnosis is currently made using imaging techniques, such as computed tomography and magnetic resonance imaging (MRI). For most cirrhotic patients, these methods are enough for diagnosis, foregoing the necessity of a liver biopsy[9-11]. Nevertheless, the precise diagnosis of a liver nodule *via* imaging techniques is a rather challenging task, requiring a highly trained and specialized multidisciplinary team of radiologists, hepatologists and oncologists.

In order to facilitate communication between professionals of such a team, a system for reporting imaging of liver nodules has been developed and adopted worldwide–the Liver Imaging Reporting And Data System (LI-RADS)[12]. The LI-RADS classification[13] can be found in Table 1. Although this was an attempt into standardization, a high discordance rate among radiologists has been described[14]. Inter-rater reliability has varied greatly in studies, with Cohen’s kappa coefficients ranging from 0.35 to 0.73[15-19]. This is expected, since this classification requires high-quality imaging and radiologists with vast experience[19,20]. Another very important argument is that where HCC incidence is higher (developing countries), highly specialized radiologists are scarcest despite a high volume of patients[21]. In order to improve outcomes and bypass these obstacles, many companies and clinical centers have been trying to develop deep learning systems (DLS) intended to accurately diagnose liver nodules in the cirrhotic liver[22].

**DLS and HCC**

There are many DLS approaches available in the literature, where neural networks are gaining much attention currently as one of the best approaches to accurately diagnose liver nodules. Particularly, a DLS based on convolutional neural networks (CNN) could achieve such capacities after machine learning (ML) by using examples of images with and without the disease in question[8]. Unlike other DLS, CNN does not demand a clear definition of the lesion in order to interpret the images[23], which might lead to discovery of additional differential characteristics that are not currently known by radiologists[24]. Table 2 summarizes the main characteristics about the studies in diagnosis of liver tumors with images and clinical data using DLS.

There are several DLS applied in the recognition of image patterns[25,26], from which CNN-based approaches have achieved the highest performance[25]. While conventional deep learning algorithms require specific features to be extracted from images before the learning process, the application of CNNs requires rather a simpler feature representation based on the original image pixel intensities, also allowing to use all available image information in the learning process[27]. Moreover, CNNs can process extracted image features by several convolution filters, which allow analysis of the image at different granularities. Therefore, CNN is one of the most advanced techniques for artificial intelligence[25], which has been implemented with success for imaging and clinical interpretation in many medical fields. For example, CNN has been validated to identify liver tumors[28], the prognosis of esophageal variceal bleeding in cirrhotic patients[29], to predict the mortality of liver transplantation[30, 31], to predict the prognosis of HCC[32-37] *Helicobacter* *pylori* infection[38], colonic polyps[39], to help classify mammary cancer, head and neck cancer and gliomas[36] and to focal liver disease detection[40].

In the topic of liver tumors, many studies have shown that CNNs performed the same or better when compared to experienced radiologists. Hamm *et al*[8] developed and validated a CNN that classified six types of common hepatic lesions on multi-phasic MRI, achieving better sensitivity and specificity when compared to board-certified radiologists[8]. Nevertheless, this study was developed in only one center, using local and typical images, with no external validation. In a follow-up to this study, Wang *et al*[41] used a pre-trained CNN in a model-agonistic approach capable of distinguishing among several types of lesions and developed a post-hoc algorithm with the purpose of standardizing the lesion features used in the diagnosis. Such a tool could interact with other standardized scales, such as LI-RADS, validating auxiliary resources and improving clinical practicality[41]. This study found a sensitivity of 82.9% for adequate identification of imaging characteristics when analyzing lesions from a databank. It is expected that this type of DLS that can be transparent regarding its steps towards the diagnosis will have better clinical acceptance.

Yamashita *et al*[14] developed a DLS applied to diagnose liver carcinoma by using two CNNs: a pre-trained network with an input of triple-phase images (trained with transfer learning from other CNNs) and a custom-made network with an input of quadruple-phase images (trained from scratch from internal data)[14]. However, by using external data from other pre-trained CNNs, Zech *et al*[42] showed that the performance of the DLS worsened when compared to CNNs trained with internal data, showing that it is not still proved that CNNs trained on X-rays from one hospital or one group of hospitals will work equally well at different hospitals. This has also been demonstrated for the detection of pneumonia in chest X-rays, where CNN performed worse when exposed to external data with a wide range of diseases and radiological findings[42]. Besides, such CNNs could be used for the determination of LI-RADS category, which has been shown to be possible[14], even from a small data set. Nevertheless, external validation seems to be a major obstacle for the dissemination of ML tools. There are many devices that produce images, and there are many ways to store data from these exams.

When compared to other DLS, another advantage of the use of CNNs is that it can improve the diagnosis by using less images for ML, reducing the time of exam and the amount of exposure to radiation[23,43,44]. Moreover, by generating additional training samples through data augmentation, the liver lesion classification sensitivity and accuracy are enhanced whilst less images are required in the ML process[45]. Moreover, the sensitivity, specificity, and accuracy can be manually calculated with the confusion matrix. In Table 3, we compare the best ML algorithms for classification[46].

A DLS has been proposed for the prediction of HCC recurrence, using data from computed tomography combined with clinical information[47]. The triple layer model including imaging studies, clinical data and a filtering of this data has had the better performance, with an area under the receiver operating characteristic curve (AUROC) of 0.825. This is way more precise than the current tools are. Furthermore, Sato *et al*[48] proposed a ML model for predicting HCC using data obtained during clinical practice[48]. The AUROC of the optimal hyperparameter, gradient boosting model, involving multiple laboratories and tumor markets was 0.940. However, when compared with single tumor markers the AUROC to the prediction of HCC for alpha-fetoprotein, des-gamma-carboxy prothrombin and alpha-fetoprotein-L3 were 0.766, 0.644 and 0.683, respectively. Accordingly, a combination of multiple data can provide a reliable diagnostic tool.

A preliminary study has attempted to diagnose liver masses using a CNN without the aid of a radiologist, achieving a high accuracy to differentiate HCC from benign liver masses, achieving an AUROC of 0.92[25]. In another study, a CNN was designed to differentiate HCC from metastatic liver masses on MRI, but this time the DLS used a 3-D representation, with higher accuracy (83.0% of the 3-D model *vs* 65.2% of the 2-D model)[28]. Nevertheless, the authors stressed that more studies with larger databanks are needed to verify the accuracy of this method. Besides that, Naeem *et al*[49] performed a hybrid-feature analysis between computed tomography scans and MRI for differentiation of liver tumors using DLS. The accuracy of multilayer perceptron model for hepatoblastoma, cyst, hemangioma, hepatocellular adenoma, HCC and metastasis were 99.67%, 99.33%, 98.33%, 99.67%, 97.33% and 99.67% respectively[49]. This method can be helpful to reduce human error.

Therefore, despite the advances in DLS for the diagnosis of imaging techniques, there are many points that need better development in order to become useful and common tools in daily practice. These techniques currently require comparison with trained radiologists and the application for many databanks with atypical images to achieve better results and the use of less radiation for HCC diagnosis.

We previously presented several DLS applied to liver nodule diagnosis; however, they are not able to segment the nodule from the liver in the analyzed images. Moreover, automatic nodule segmentation in an image is a challenging task since this kind of lesion may show a high variability in shape, appearance and localization and is dependent on the equipment, contrast, lesion type, lesion stage and so on[50].

There are some liver nodule segmentation methods available in the literature, and in one of them[50] a fully convolutional network architecture was adopted to determine an approximation for where the nodule was located on the image. This CNN works on four resolution levels, learning local and global image features. The final nodule segmentation is obtained by using post-processing techniques and a random forest classifier, achieving a quality comparable to a human expert.

However, this method uses hand-crafted features that need the supervision of an expert. There are also automatic approaches that can segment the nodule[51], where a CNN is used for ML. To refine the segmentation results, this method applies conditional random fields to eliminate the false segmentation points in the segmentation results, improving accuracy. However, liver nodule segmentation in general still needs improvements to achieve a better accuracy and practical applicability. Furthermore, it is necessary for more research effort in DLS to at the same time detect the tumor in the liver and segment it on the image.

**CONCLUSION**

In conclusion, the goal of statistical methods is to achieve conclusions about a population from data that are collected from a representative sample of that population, such as linear and logistic regression. Therefore, the objective is to comprehend the associations among variables. However, as reported by Sidey-Gibbons andSidey-Gibbons[36], the primary concern about DLS is an accurate prediction. Moreover, explaining the relationship between predictors and outcomes when the relationship is non-linear is difficult. However, in several DLS as improving navigation, translating documents or recognizing objects in videos, understanding the relationship between features and outcomes is less important[46]. In summary, enhancement of DLS features will allow more accurate diagnosis in the medical field. For future research, we recommend to test deep learning methods in other datasets (*e.g.*, other hospitals), develop an easy usable interface and introduce the tool in daily medical practice.

**REFERENCES**

1 **Soldera J**, Balbinot SS, Balbinot RA, Cavalcanti AG. Diagnostic and Therapeutic Approaches to Hepatocellular Carcinoma: Understanding the Barcelona Clínic Liver Cancer Protocol. *Clin Med Insights Gastroenterol* 2016; **9**: 67-71 [PMID: 27812296 DOI: 10.4137/CGast.S30190]

2 **El-Serag HB**, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007; **132**: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]

3 **Bosetti C**, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. *Best Pract Res Clin Gastroenterol* 2014; **28**: 753-770 [PMID: 25260306 DOI: 10.1016/j.bpg.2014.08.007]

4 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020; **70**: 7-30 [PMID: 31912902 DOI: 10.3322/caac.21590]

5 **Onzi G,** Moretti F, Balbinot SS, Balbinot RA, Soldera J. Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis. *Hepatoma Res* 2019; **5** [DOI: 10.20517/2394-5079.2018.114]

6 **Margini C**, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. *Liver Int* 2016; **36**: 317-324 [PMID: 26601627 DOI: 10.1111/liv.13031]

7 **Soldera J,** Balbinot SS, Balbinot RA, Furlan RG, Terres AZ. Advanced hepatocellular carcinoma. *Austin J Gastroenterol* 2017; **4:** 1088.[cited 20 March 2021].Available from: https://austinpublishinggroup.com/gastroenterology/fulltext/ajg-v4-id1088.php

8 **Hamm CA**, Wang CJ, Savic LJ, Ferrante M, Schobert I, Schlachter T, Lin M, Duncan JS, Weinreb JC, Chapiro J, Letzen B. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI. *Eur Radiol* 2019; **29**: 3338-3347 [PMID: 31016442 DOI: 10.1007/s00330-019-06205-9]

9 **Marrero JA**, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018; **68**: 723-750 [PMID: 29624699 DOI: 10.1002/hep.29913]

10 **European Association for the Study of the Liver.** EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]

11 **Chagas AL**, Mattos AA, Carrilho FJ, Bittencourt PL; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA. Brazilian society of hepatology updated recommendations for diagnosis and treatment of hepatocellular carcinoma. *Arq Gastroenterol* 2020; **57**: 1-20 [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20]

12 **Elsayes KM**, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. *J Hepatocell Carcinoma* 2019; **6**: 49-69 [PMID: 30788336 DOI: 10.2147/JHC.S186239]

13 **Elsayes KM**, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System: an expert consensus statement. *J Hepatocell Carcinoma* 2017; **4**: 29-39 [PMID: 28255543 DOI: 10.2147/JHC.S125396]

14 **Yamashita R**, Mittendorf A, Zhu Z, Fowler KJ, Santillan CS, Sirlin CB, Bashir MR, Do RKG. Deep convolutional neural network applied to the liver imaging reporting and data system (LI-RADS) version 2014 category classification: a pilot study. *Abdom Radiol (NY)* 2020; **45:** 24-35 [PMID: 31696269 DOI: 10.1007/s00261-019-02306-7]

15 **Fowler KJ**, Tang A, Santillan C, Bhargavan-Chatfield M, Heiken J, Jha RC, Weinreb J, Hussain H, Mitchell DG, Bashir MR, Costa EAC, Cunha GM, Coombs L, Wolfson T, Gamst AC, Brancatelli G, Yeh B, Sirlin CB. Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study. *Radiology* 2018; **286**: 173-185 [PMID: 29091751 DOI: 10.1148/radiol.2017170376]

16 **Schellhaas B**, Hammon M, Strobel D, Pfeifer L, Kielisch C, Goertz RS, Cavallaro A, Janka R, Neurath MF, Uder M, Seuss H. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS. *Eur Radiol* 2018; **28**: 4254-4264 [PMID: 29675659 DOI: 10.1007/s00330-018-5379-1]

17 **Barth BK**, Donati OF, Fischer MA, Ulbrich EJ, Karlo CA, Becker A, Seifert B, Reiner CS. Reliability, Validity, and Reader Acceptance of LI-RADS-An In-depth Analysis. *Acad Radiol* 2016; **23**: 1145-1153 [PMID: 27174029 DOI: 10.1016/j.acra.2016.03.014]

18 **Davenport MS**, Khalatbari S, Liu PS, Maturen KE, Kaza RK, Wasnik AP, Al-Hawary MM, Glazer DI, Stein EB, Patel J, Somashekar DK, Viglianti BL, Hussain HK. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. *Radiology* 2014; **272**: 132-142 [PMID: 24555636 DOI: 10.1148/radiol.14131963]

19 **Blachar A**, Federle MP, Ferris JV, Lacomis JM, Waltz JS, Armfield DR, Chu G, Almusa O, Grazioli L, Balzano E, Li W. Radiologists' performance in the diagnosis of liver tumors with central scars by using specific CT criteria. *Radiology* 2002; **223**: 532-539 [PMID: 11997564 DOI: 10.1148/radiol.2232010801]

20 **Dubus L**, Gayet M, Zappa M, Abaleo L, De Cooman A, Orieux G, Vilgrain V. Comparison of semi-automated and manual methods to measure the volume of liver tumours on MDCT images. *Eur Radiol* 2011; **21**: 996-1003 [PMID: 21132500 DOI: 10.1007/s00330-010-2013-2]

21 **Nayak A**, Baidya Kayal E, Arya M, Culli J, Krishan S, Agarwal S, Mehndiratta A. Computer-aided diagnosis of cirrhosis and hepatocellular carcinoma using multi-phase abdomen CT. *Int J Comput Assist Radiol Surg* 2019; **14**: 1341-1352 [PMID: 31062266 DOI: 10.1007/s11548-019-01991-5]

22 **Azer SA**. Deep learning with convolutional neural networks for identification of liver masses and hepatocellular carcinoma: A systematic review. *World J Gastrointest Oncol* 2019; **11**: 1218-1230 [PMID: 31908726 DOI: 10.4251/wjgo.v11.i12.1218]

23 **Shi W**, Kuang S, Cao S, Hu B, Xie S, Chen S, Chen Y, Gao D, Chen Y, Zhu Y, Zhang H, Liu H, Ye M, Sirlin CB, Wang J. Deep learning assisted differentiation of hepatocellular carcinoma from focal liver lesions: choice of four-phase and three-phase CT imaging protocol. *Abdom Radiol (NY)* 2020; **45**: 2688-2697 [PMID: 32232524 DOI: 10.1007/s00261-020-02485-8]

24 **Greenspan H,** Van Ginneken B, Summers RM. Guest editorial deep learning in medical imaging: Overview and future promise of an exciting new technique. *IEEE Trans Med Imag* 2016; **35:** 1153-1159 [DOI: 10.1109/TMI.2016.2553401]

25 **Yasaka K**, Akai H, Abe O, Kiryu S. Deep Learning with Convolutional Neural Network for Differentiation of Liver Masses at Dynamic Contrast-enhanced CT: A Preliminary Study. *Radiology* 2018; **286**: 887-896 [PMID: 29059036 DOI: 10.1148/radiol.2017170706]

26 **Fukushima K,** Miyake S. Neocognitron: A new algorithm for pattern recognition tolerant of deformations and shifts in position. *Pat Recog* 1982; **15:** 455-469 [DOI: 10.1016/0031-3203(82)90024-3]

27 **LeCun Y**, Bengio Y, Hinton G. Deep learning. *Nature* 2015; **521**: 436-444 [PMID: 26017442 DOI: 10.1038/nature14539]

28 **Trivizakis E**, Manikis GC, Nikiforaki K, Drevelegas K, Constantinides M, Drevelegas A, Marias K. Extending 2-D Convolutional Neural Networks to 3-D for Advancing Deep Learning Cancer Classification With Application to MRI Liver Tumor Differentiation. *IEEE J Biomed Health Inform* 2019; **23**: 923-930 [PMID: 30561355 DOI: 10.1109/JBHI.2018.2886276]

29 **Soldera J,** Tomé F, Corso LL, Rech MM, Ferrazza AD, Terres AZ, Cini BT, Eberhardt LZ, Balensiefer JIL, Balbinot RS, Muscope ALF, Longen ML, Schena B, Rost GL Jr, Furlan RG, Balbinot RA, Balbinot SS. Use of a machine learning algorithm to predict rebleeding and mortality for oesophageal variceal bleeding in cirrhotic patients. *EMJ Gastroenterol* 2020; **9:** 46-48. [cited 20 March 2021].Available from: https://www.emjreviews.com/gastroenterology/abstract/use-of-a-machine-learning-algorithm-to-predict-rebleeding-and-mortality-for-oesophageal-variceal-bleeding-in-cirrhotic-patients/

30 **Soldera J,** Tomé F, Corso LL, Ballotin VR, Bigarella LG, Balbinot RS, Rodriguez S, Brandão AB, Hochhegger B. 590 Predicting 30 and 365-day mortality after liver transplantation using a machine learning algorithm. *Gastroenterology* 2021; **160**: S-789-S-790 [DOI: 10.1016/S0016-5085(21)02602-0]

31 **Wingfield LR**, Ceresa C, Thorogood S, Fleuriot J, Knight S. Using Artificial Intelligence for Predicting Survival of Individual Grafts in Liver Transplantation: A Systematic Review. *Liver Transpl* 2020; **26**: 922-934 [PMID: 32274856 DOI: 10.1002/lt.25772]

32 **Lai Q**, Spoletini G, Mennini G, Laureiro ZL, Tsilimigras DI, Pawlik TM, Rossi M. Prognostic role of artificial intelligence among patients with hepatocellular cancer: A systematic review. *World J Gastroenterol* 2020; **26**: 6679-6688 [PMID: 33268955 DOI: 10.3748/wjg.v26.i42.6679]

33 **Sato M**, Tateishi R, Yatomi Y, Koike K. Artificial intelligence in the diagnosis and management of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2021; **36**: 551-560 [PMID: 33709610 DOI: 10.1111/jgh.15413]

34 **Yi PS,** Hu CJ, Li CH, Yu F. Clinical value of artificial intelligence in hepatocellular carcinoma: Current status and prospect. *Artif Intell Gastroenterol* 2021; **2**: 42-55 [DOI: 10.35712/aig.v2.i2.42]

35 **Chang KP,** Lin SH, Chu YW. Artificial intelligence in gastrointestinal radiology: A review with special focus on recent development of magnetic resonance and computed tomography. *Artif Intell Gastroenterol* 2021; **2**: 27-41 [DOI: 10.35712/aig.v2.i2.27]

36 **Verde F,** Romeo V, Stanzione A, Maurea S. Current trends of artificial intelligence in cancer imaging. *Artif Intell Med Imaging* 2020; **1**: 87-93 [DOI: 10.35711/aimi.v1.i3.87]

37 **Kudou M,** Kosuga T, Otsuji E. Artificial intelligence in gastrointestinal cancer: Recent advances and future perspectives. *Artif Intell Gastroenterol* 2020; **1**: 71-85 [DOI: 10.35712/aig.v1.i4.71]

38 **Morreale GC,** Sinagra E, Vitello A, Shahini E, Shahini E, Maida M. Emerging artificial intelligence applications in gastroenterology: A review of the literature. *Artif Intell Gastrointest Endosc* 2020; **1**:6-18 [DOI: 10.37126/aige.v1.i1.6]

39 **Li JW,** Ang TL. Colonoscopy and artificial intelligence: Bridging the gap or a gap needing to be bridged? *Artif Intell Gastrointest Endosc* 2021; **2**: 36-49 [DOI: 10.37126/aige.v2.i2.36]

40 **Masuzaki R,** Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Moriyama M. Application of artificial intelligence in hepatology: Minireview. *Artif Intell Gastroenterol* 2020; **1**:5-11 [DOI: 10.35712/aig.v1.i1.5]

41 **Wang CJ**, Hamm CA, Savic LJ, Ferrante M, Schobert I, Schlachter T, Lin M, Weinreb JC, Duncan JS, Chapiro J, Letzen B. Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using radiologic imaging features. *Eur Radiol* 2019; **29**: 3348-3357 [PMID: 31093705 DOI: 10.1007/s00330-019-06214-8]

42 **Zech JR**, Badgeley MA, Liu M, Costa AB, Titano JJ, Oermann EK. Variable generalization performance of a deep learning model to detect pneumonia in chest radiographs: A cross-sectional study. *PLoS Med* 2018; **15**: e1002683 [PMID: 30399157 DOI: 10.1371/journal.pmed.1002683]

43 **Li M**, Hsu W, Xie X, Cong J, Gao W. SACNN: Self-Attention Convolutional Neural Network for Low-Dose CT Denoising With Self-Supervised Perceptual Loss Network. *IEEE Trans Med Imaging* 2020; **39**: 2289-2301 [PMID: 31985412 DOI: 10.1109/TMI.2020.2968472]

44 **Chen H**, Zhang Y, Kalra MK, Lin F, Chen Y, Liao P, Zhou J, Wang G. Low-Dose CT With a Residual Encoder-Decoder Convolutional Neural Network. *IEEE Trans Med Imaging* 2017; **36**: 2524-2535 [PMID: 28622671 DOI: 10.1109/TMI.2017.2715284]

45 **Frid-Adar M,** Diamant I, Klang E, Amitai M, Goldberger J, Greenspan H. GAN-based synthetic medical image augmentation for increased CNN performance in liver lesion classification. *Neurocomputing* 2018; **321**: 321-331 [DOI: 10.1016/j.neucom.2018.09.013]

46 **Sidey-Gibbons JAM**, Sidey-Gibbons CJ. Machine learning in medicine: a practical introduction. *BMC Med Res Methodol* 2019; **19**: 64 [PMID: 30890124 DOI: 10.1186/s12874-019-0681-4]

47 **Wang W**, Chen Q, Iwamoto Y, Han X, Zhang Q, Hu H, Lin L, Chen YW. Deep Learning-Based Radiomics Models for Early Recurrence Prediction of Hepatocellular Carcinoma with Multi-phase CT Images and Clinical Data. *Annu Int Conf IEEE Eng Med Biol Soc* 2019; **2019**: 4881-4884 [PMID: 31946954 DOI: 10.1109/EMBC.2019.8856356]

48 **Sato M**, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. *Sci Rep* 2019; **9**: 7704 [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8]

49 **Naeem S,** Ali A, Qadri S, Mashwani WK, Tairan N, Shah H, Fayaz M, Jamal F, Chesneau C, Anam S. Machine-Learning based hybrid-feature analysis for liver cancer classification using fused (MR and CT) images. *Appl Sci* 2020; **10**: 3134 [DOI: 10.3390/app10093134]

50 **Bousabarah K,** Letzen B, Tefera J, Savic L, Schobert I, Schlachter T, Staib LH, Kocher M, Chapiro J, Lin M. Automated detection and delineation of hepatocellular carcinoma on multiphasic contrast-enhanced MRI using deep learning. *Abdom Radiol* 2020; 1-10 [DOI: 10.1007/s00261-020-02604-5]

51 **Meng L**, Tian Y, Bu S. Liver tumor segmentation based on 3D convolutional neural network with dual scale. *J Appl Clin Med Phys* 2020; **21**: 144-157 [PMID: 31793212 DOI: 10.1002/acm2.12784]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflict of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author’s Membership in Professional Societies:** Federação Brasileira De Gastroenterologia.

**Peer-review started:** April 21, 2021

**First decision:** May 19, 2021

**Article in press:** July 19, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Hameed MM, Raut V, Zhang L, Zhu YY **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Ma YJ

**Table 1 Liver imaging reporting and data system classification[13]**

|  |  |
| --- | --- |
| **Category** | **Description** |
| LR-1 | Definitely benign |
| LR-2 | Probably benign |
| LR-3 | Intermediate probability of HCC |
| LR-4 | High probability of HCC, not 100% |
| LR-5 | Definitely HCC |
| LR-5V | Definite venous invasion regardless of other imaging features  |
| LR treated | LR-5 lesion status post-locoregional treatment |
| LR-M | Non-HCC malignancies that may occur in cirrhosis: metastases, lymphoma, cholangiocarcinoma, PTLD |

HCC: Hepatocellular carcinoma; PTLD: Post-transplant lymphoproliferative disorder.

**Table 2 Main characteristics of the studies that evaluate deep learning for liver tumor diagnosis throughout images or clinical data**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Deep learning method** | **Accuracy** | **Sensitivity** | **Specificity** | **AUROC** | **DLS performance compared**  | **Multicenter validation** | **Conclusion** |
| Hamm *et al*[8], 2019 | United States | Proof-of-concept validation CNN | 92% | 92% | 98% | 0.992 | Better than radiologists | Not done | DLS was feasibility for classifying lesions with typical imaging features from six common hepatic lesion types. |
| Yamashita *et al*[14], 2020 | United States | CNN architectures: custom-made network and transfer learning-based network | 60.4% | NA | NA | LR-1/2: 0.85. LR-3: 0.90. LR-4: 0.63. LR-5: 0.82. | Transfer learning model was better | Performed | There is a feasibility of CNN for assigning LI-RADS categories from a relatively small dataset but highlights the challenges of model development and validation. |
| Shi *et al*[23], 2020 | China | Three CDNs | Model-A: 83.3%, B: 81.1%, C: 85.6%  | NA | NA | Model-A: 0.925; B: 0.862; C: 0.920 | Three model compared, A and C with better results | Not done | Three-phase CT protocol without precontrast showed similar diagnosis accuracy as four-phase protocol in differentiating HCC. It can reduce the radiation dose |
| Yasaka *et al*[25], 2018 | Japan | CNN | 84% | Category1: A: 71%; B: 33%; C: 94%; D: 90%; E: 100% | NA | 0.92 | Not applicable | Not done | Deep learning with CNN showed high diagnostic performance in differentiation of liver masses at dynamic CT |
| Trivizakis *et al*[28], 2019 | Greece | 3D and 2D CNN | 83% | 93% | 67% | 0.80 | Superior compared with 2D CNN model | Not done | 3D CNN architecture can bring significant benefit in DW-MRI liver discrimination and potentially in numerous other tissue classification problems based on tomographic data, especially in size-limited, disease specific clinical datasets |
| Wang *et al*[41], 2019 | United States | Proof-of-concept “interpretable” CNN | 88% | 82.9% | NA | NA | Not applicable | Not done | This interpretable deep learning system demonstrates proof of principle for illuminating portions of a pre-trained deep neural network’s decision-making, by analyzing inner layers and automatically describing features contributing to predictions |
| Frid-Adar *et al*[45], 2018 | Israel | GANs | Classic data: 78.6%. Synthetic data: 85.7% | Classic data: 78.6%. Synthetic data: 85.7% | Classic data: 88.4%. Synthetic data: 92.4% | NA | Synthetic data augmentation is better than classic data augmentation | Not done | This approach to synthetic data augmentation can generalize to other medical classification applications and thus support radiologists’ efforts to improve diagnosis |
| Wang *et al*[47], 2019 | Japan | CNN with clinical data | NA | NA | NA | Clinical model: 0.723. Model: A: 0.788; B: 0.805; C: 0825. | Combined model C present with better results  | Not done | The AUC of the combined model is about 0.825, which is much better than the models using clinical data only or CT image only |
| Sato *et al*[48], 2019 | Japan | Fully connected neural network with 4 layers of neurons using only biomarkers, gradient boosting (non-linear model) and others | DLS: 83.54%. Gradient boosting: 87.34% | Gradient boosting: 93.27% | Gradient boosting: 75.93% | DLS: 0.884. Gradient boosting: 0.940 | Deep learning was not the optimal classifier in the current study | Not done | The gradient boosting model reduced the misclassification rate by about half compared with a single tumor marker. The model can be applied to various kinds of data and thus could potentially become a translational mechanism between academic research and clinical practice |
| Naeem *et al*[49], 2020 | Pakistan | MLP, SVM, RF, and J48 using ten-fold cross-validation  | MLP: 99% | NA | NA | MLP: 0.983. SVM: 0.966. RF: 0.964. J48: 0.959 | MLP model present with better results | Radiopaedia dataset | Our proposed system has the capability to verify the results on different MRI and CT scan databases, which could help radiologists to diagnose liver tumors |

1Five categories: A: Classic hepatocellular carcinomas; B: Malignant liver tumors other than classic and early hepatocellular carcinomas; C: Indeterminate masses or mass like lesions (including early hepatocellular carcinomas and dysplastic nodules) and rare benign liver masses other than hemangiomas and cysts; D: Hemangiomas; E: Cysts. AUC: Area under the curve; AUROC: Area under the receiver operating characteristic curve; CDNs: Convolutional dense networks CNN: Convolutional neural network; CT: Computed tomography; DLS: Deep learning system; DW-MRI: Diffusion weighted magnetic resonance imaging; GANs: Generative adversarial networks; HCC: Hepatocellular carcinoma; LI-RADS: Liver Imaging Reporting and Data System; LR: LI-RADS; MLP: Multiplayer perceptron; MRI: Magnetic resonance imaging; NA: Not available; RF: Random forest; SVM: Support vector machine.

**Table 3 Best machine learning algorithms for classification[36]**

|  |  |  |
| --- | --- | --- |
| **Algorithm** | **Pros** | **Cons** |
| Naïve Bayes Classifier | Simple, easy and fast. Not sensitive to irrelevant features. Works great in practice. Needs less training data. For both multi-class and binary classification. Works with continuous and discrete data | Accepts every feature as independent. This is not always the truth. |
| Decision Trees | Easy to understand. Easy to generate rules. There are almost no hyperparameters to be tuned. Complex decision tree models can be significantly simplified by its visualizations | Might suffer from overfitting. Does not easily work with nonnumerical data. Low prediction accuracy for a dataset in comparison with other algorithms. When there are many class labels, calculations can be complex |
| Support Vector Machines | Fast algorithm. Effective in high dimensional spaces. Great accuracy. Power and flexibility from kernels. Works very well with a clear margin of separation. Many applications | Does not perform well with large data sets. Not so simple to program. Does not perform so well when the data comes with more noise *i.e.* target classes are overlapping |
| Random Forest Classifier | The overfitting problem does not exist. Can be used for feature engineering *i.e.* for identifying the most important features among all available features in the training dataset. Runs very well on large databases. Extremely flexible and have very high accuracy. No need for preparation of the input data | Complexity. Requires a lot of computational resources. Time-consuming. Need to choose the number of trees |
| KNN Algorithm | Simple to understand and easy to implement. Zero to little training time. Works easily with multi-class data sets. Has good predictive power. Does well in practice | Computationally expensive testing phase. Can have skewed class distributions. The accuracy can be decreased when it comes to high-dimension data. Needs to define a value for the parameter k |

KNN: K-nearest neighbors.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**